Collegium Pharmaceutical, Inc. logo COLL - Collegium Pharmaceutical, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 3
SELL 1
STRONG
SELL 0
| PRICE TARGET: $48.00 DETAILS
HIGH: $50.00
LOW: $45.00
MEDIAN: $48.50
CONSENSUS: $48.00
UPSIDE: 106.99%

Stock News

Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut

Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut

Collegium Pharmaceutical is rated a high-risk Buy after a sharp guidance cut and stock drop, with the market pricing in an overly pessimistic scenario. ADHD drugs Jornay PM and AZSTARYS now account for over 30% of 2026 sales, are growing robustly, and enjoy patent protection into the 2030s. Pain franchise decline is staged, with Nucynta facing immediate generic pressure, Belbuca's patent risk centered on an April 2027 trial, and Xtampza protected until 2033.

Oct 17, 2026 08:18 AM • seekingalpha.com
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

STOUGHTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, launched Start Talking ADHD, an online resource hub offering practical guides to people living with attention-deficit/hyperactivity disorder (ADHD), and the families who support them.

Oct 06, 2026 04:00 AM • globenewswire.com
44,493 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Freestone Grove Partners LP

44,493 Shares in Collegium Pharmaceutical, Inc. $COLL Purchased by Freestone Grove Partners LP

Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ: COLL) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 44,493 shares of the specialty pharmaceutical company's stock, valued at approximately $1,611,000. Freestone Grove Partners LP owned

Aug 30, 2026 12:23 AM • defenseworld.net
BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL

BlackRock Inc. Takes $196.97 Million Position in Collegium Pharmaceutical, Inc. $COLL

BlackRock Inc. bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ: COLL) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,441,202 shares of the specialty pharmaceutical company's stock, valued at approximately $196,972,000. BlackRock Inc. owned about 16.78% of Collegium

Aug 28, 2026 12:12 AM • defenseworld.net
Collegium Announces $50 Million Accelerated Share Repurchase Program

Collegium Announces $50 Million Accelerated Share Repurchase Program

STOUGHTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $50 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in July 2025. Upon completion of this ASR, Collegium will have $100 million remaining under the program.

Aug 13, 2026 03:30 AM • globenewswire.com
Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey

Avenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey

Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Avenue Therapeutics (NASDAQ: ATXI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership. Profitability This table compares Collegium Pharmaceutical and

Aug 12, 2026 11:33 PM • defenseworld.net
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress

– Completed Acquisition of AZSTARYS ® , Strengthening ADHD Portfolio and Extending Long-Term Revenue Outlook – – Generated Quarterly Net Revenues of $199.9 Million, Up 6% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $46.1 Million, Up 41% Year-over-Year – – Generated AZSTARYS Quarterly Net Revenue of $12.9 Million, Representing a Partial Quarter of Sales – – Generated Quarterly Pain Portfolio Net Revenues of $140.9 Million – – Updates Full-Year 2026 Financial Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.

Aug 06, 2026 03:30 AM • globenewswire.com
Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical: Pain Cash Flows Are Funding An ADHD Re-Rating

Collegium Pharmaceutical (COLL) is transitioning from a pain-management roll-up to a CNS platform, leveraging stable pain cash flows to fuel ADHD franchise growth. The AZSTARYS acquisition, funded with $350M cash and $300M debt, is expected to deliver $60–70M revenue in 2026 and $50M+ annual synergies within 12 months. COLL's 2026 guidance is $865–895M in revenue and $475–500M adjusted EBITDA, with a 55% margin, reflecting only partial-year AZSTARYS contribution and early synergies.

Aug 01, 2026 10:12 AM • seekingalpha.com
DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln

DivcoWest Welcomes Collegium Pharmaceutical to One Lincoln

BOSTON--(BUSINESS WIRE)--DivcoWest, a DivCore Capital company and national commercial real estate investment firm, today announced that Collegium Pharmaceutical, a leading biopharmaceutical company, has signed a lease for 40,288 square feet on floors 11 and 12 at One Lincoln in Boston's Financial District. The 36‑story, 1.1‑million‑square‑foot Class A office tower completed a transformative renewal in 2025 and now serves as a landmark next-generation workplace for world-class established and gr.

Jul 20, 2026 04:33 AM • businesswire.com

Price Targets